 | • レポートコード：MRC2303J0056 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、248ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に249.8億ドルであった世界の治療用ワクチン市場規模は、2022年に273.9億ドルになり、2027年までにCAGR 9.93％で拡大して440.9億ドルに達するとみられています。本書は、治療用ワクチンの世界市場を対象とした調査結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、ワクチン種類別（自己免疫疾患ワクチン、慢性疾患ワクチン、感染症ワクチン、神経疾患ワクチン）分析、疾患別（DTP、デング熱、肝炎、ヒトパピローマウイルス、インフルエンザ）分析、投与方法別（筋肉内＆皮下投与、経口投与）分析、エンドユーザー別（成人、小児）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、下記の項目を掲載しています。なお、本書内の企業情報としては、Astellas Pharma, Inc.、CSL Limited、Emergent Biosolutions, Inc.、GlaxoSmithKline PLC、Johnson & Johnson、MedImmune, LLC、Merck & Co., Inc.、Pfizer, Inc.、Sanofi Pasteur SA、The Serum Institute of Indiaなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の治療用ワクチン市場規模：ワクチン種類別 - 自己免疫疾患ワクチンの市場規模 - 慢性疾患ワクチンの市場規模 - 感染症ワクチンの市場規模 - 神経疾患ワクチンの市場規模 ・世界の治療用ワクチン市場規模：疾患別 - DTPにおける市場規模 - デング熱ワクチンの市場規模 - 肝炎ワクチンの市場規模 - ヒトパピローマウイルスワクチンの市場規模 - インフルエンザワクチンの市場規模 ・世界の治療用ワクチン市場規模：投与方法別 - 筋肉内＆皮下投与ワクチンの市場規模 - 経口投与ワクチンの市場規模 ・世界の治療用ワクチン市場規模：エンドユーザー別 - 成人における市場規模 - 小児における市場規模 ・世界の治療用ワクチン市場規模：地域別 - 南北アメリカの治療用ワクチン市場規模 アメリカの治療用ワクチン市場規模 カナダの治療用ワクチン市場規模 ブラジルの治療用ワクチン市場規模 ... - アジア太平洋の治療用ワクチン市場規模 日本の治療用ワクチン市場規模 中国の治療用ワクチン市場規模 インドの治療用ワクチン市場規模 韓国の治療用ワクチン市場規模 台湾の治療用ワクチン市場規模 ... - ヨーロッパ/中東/アフリカの治療用ワクチン市場規模 イギリスの治療用ワクチン市場規模 ドイツの治療用ワクチン市場規模 フランスの治療用ワクチン市場規模 ロシアの治療用ワクチン市場規模 ... - その他地域の治療用ワクチン市場規模 ・競争状況 ・企業情報 |
The Global Therapeutic Vaccines Market size was estimated at USD 24.98 billion in 2021 and expected to reach USD 27.39 billion in 2022, and is projected to grow at a CAGR 9.93% to reach USD 44.09 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Therapeutic Vaccines to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Vaccines Type, the market was studied across Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines, and Neurological Disease Vaccines.
Based on Disease Indication, the market was studied across DTP, Dengue, Hepatitis, Human Papilloma Virus, Influenza, MMR, Meningococcal Disease, Pneumococcal Disease, Polio, and Varicella.
Based on Administration, the market was studied across Intramuscular and Subcutaneous Administration and Oral Administration.
Based on End User, the market was studied across Adults and Pediatrics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Therapeutic Vaccines market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Therapeutic Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Therapeutic Vaccines Market, including Astellas Pharma, Inc., CSL Limited, Emergent Biosolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson, MedImmune, LLC, Merck & Co., Inc., Pfizer, Inc., Sanofi Pasteur SA, and The Serum Institute of India.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Therapeutic Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Therapeutic Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Therapeutic Vaccines Market?
4. What is the competitive strategic window for opportunities in the Global Therapeutic Vaccines Market?
5. What are the technology trends and regulatory frameworks in the Global Therapeutic Vaccines Market?
6. What is the market share of the leading vendors in the Global Therapeutic Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the Global Therapeutic Vaccines Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence rate of diseases such as chronic and infectious diseases
5.1.1.2. Rising demand for biologics and drugs for targeted diseases
5.1.1.3. Growing government funding for vaccine development
5.1.2. Restraints
5.1.2.1. Side effects associated with therapeutic vaccines
5.1.2.2. Stringent government regulations for the approval of vaccines
5.1.3. Opportunities
5.1.3.1. Growing initiatives from government and private organizations to advance vaccination
5.1.3.2. Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
5.1.3.3. Rising R&D activities and vaccines developments in the pipeline
5.1.4. Challenges
5.1.4.1. Slow processing of clinical trials for the production of some vaccine
5.1.4.2. High cost associated with the development of the therapeutic vaccines
5.2. Cumulative Impact of COVID-19
6. Therapeutic Vaccines Market, by Vaccines Type
6.1. Introduction
6.2. Auto-Immune Diseases Vaccines
6.3. Chronic Disease Vaccines
6.4. Infectious Diseases Vaccines
6.5. Neurological Disease Vaccines
7. Therapeutic Vaccines Market, by Disease Indication
7.1. Introduction
7.2. DTP
7.3. Dengue
7.4. Hepatitis
7.5. Human Papilloma Virus
7.6. Influenza
7.7. MMR
7.8. Meningococcal Disease
7.9. Pneumococcal Disease
7.10. Polio
7.11. Varicella
8. Therapeutic Vaccines Market, by Administration
8.1. Introduction
8.2. Intramuscular and Subcutaneous Administration
8.3. Oral Administration
9. Therapeutic Vaccines Market, by End User
9.1. Introduction
9.2. Adults
9.3. Pediatrics
10. Americas Therapeutic Vaccines Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Therapeutic Vaccines Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Therapeutic Vaccines Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Astellas Pharma, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. CSL Limited
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Emergent Biosolutions, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. GlaxoSmithKline PLC
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Johnson & Johnson
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. MedImmune, LLC
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Merck & Co., Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Pfizer, Inc.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Sanofi Pasteur SA
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. The Serum Institute of India
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing